Want to join the conversation?
$MYL said the US Patent and Trademark Office has ruled in its favor and found all claims of 2 related patents of Copaxone 40 mg/mL owned by Yeda Research and licensed to Teva Pharmaceuticals to be unpatentable. A decision by the Patent Trial and Appeal Board on $MYL's third petition is expected on or before Sept. 1.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.